Story
Alligator Bioscience Stock Plummets Over 70% After Halting Lead Drug Program

Alligator Bioscience (ATORX) shares plummeted more than 74% on Tuesday after the company announced it was halting the independent development of its lead oncology drug, mitazalimab, and launching an emergency capital raise to shore up its rapidly dwindling cash reserves.
The dual announcements delivered a severe blow to investor confidence, fundamentally altering the company's strategy and near-term outlook.
Pipeline Setback and Emergency Funding
Alligator's board of directors has resolved to discontinue all further in-house development of mitazalimab, its CD40-targeting antibody. The company cited a "rapidly shifting treatment landscape for pancreatic cancer" as the primary reason, concluding that continued independent investment was no longer viable. Alligator will instead attempt to out-license or sell the asset.
Compounding the pipeline news, the board simultaneously announced a proposed rights issue to raise approximately SEK 125.6 million in ordinary shares and warrants. The plan, which is subject to shareholder approval at a meeting on August 26, 2026, is supplemented by bridge loan financing to cover immediate operational needs.
Precarious Financial Position
AdThe emergency fundraising highlights the company's critical financial situation. As of the first quarter of 2026, Alligator held just SEK 33 million in cash.
This provided an operational runway extending only through the middle of the third quarter of 2026, leaving the company with little financial flexibility. The combination of a major clinical program failure and a deeply dilutive financing event triggered the massive sell-off in its shares.
Strategic Shift and Market Impact
With its lead program discontinued, Alligator plans to strategically redirect its resources. The company will now focus on the HLX22 project, an anti-HER2 antibody being developed externally by partner Shanghai Henlius Biotech. Under this arrangement, Alligator is entitled to a revenue share without bearing the development costs.
The market reaction was severe, with the stock's collapse from a 52-week high of SEK 6.04 to an intraday low of SEK 0.0324 illustrating a complete erosion of the prior investment thesis. The company is now a significantly smaller entity, reliant on the potential royalty-like economics from a single out-licensed asset.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.